Partners Biocon and Mylan have garnered about 26% market share between them for their biosimilar versions of trastuzumab in India, despite innovator Roche's alleged efforts to "fob off" competition.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?